---
document_datetime: 2024-02-27 12:53:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_en.pdf
document_name: naveruclif-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6884065
conversion_datetime: 2025-12-19 02:40:16.367702
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/23/1778/001 | Naveruclif        | 5 mg/ml    | Powder for dispersion for infusion | Intravenous use           | vial (glass)          | 100 mg                    | 1 vial      |